• Minoryx
    Minoryx
    Home
    Our Company
    Who we areManagement teamBoard of directorsScientific advisory boardFunding
    Our Science
    OverviewAdrenoleukodystrophyFriedreich's ataxia
    Our Programs
    OverviewLeriglitazone
    Clinical Studies
    Clinical Studies ADVANCEFRAMESNEXUSResourcesExpanded Access Policy
    Media
    Careers
    Follow us
    Contact
    News
    Home Media Minoryx Therapeutics to participate in upcoming investor conferences
  • Minoryx Therapeutics to participate in upcoming investor conferences
    2019-10-14

    Mataró, Barcelona, Spain and Charleroi, Belgium, October 14, 2019

    Minoryx Therapeutics, a company specializing in the development of innovative treatments for orphan Central Nervous System (CNS) diseases, today announces that its management team will participate in the two upcoming investor conferences:

    • Solebury Trout 5th Private Company Showcase featuring presentations, panels, and 1x1s with select private biotech companies on Friday, October 18, 2019 at Davis Polk & Wardwell in New York City (USA). Minoryx’ CEO to present at 1:40pm-2:00pm.
    • 10th Jefferies London Healthcare Conference to be held at the Waldorf Hilton in London on November 20-21, 2019. The two-day event will include concurrent tracks of company presentations, thematic panel discussions, and 1x1/small-group meetings. This global gathering of leading healthcare executives and institutional, private equity and venture capital investors will address near- and long-term investment opportunities and discuss the mechanisms driving global healthcare.


    About Minoryx Therapeutics

    Minoryx is a clinical stage biotech company focusing on the development of novel therapies for orphan CNS diseases with high unmet medical needs. The company’s lead program, leriglitazone (MIN-102), a novel, selective PPARγ agonist, is currently being evaluated in X-ALD and Friedreich’s Ataxia. The company is backed by a syndicate of experienced investors and has support from a network of other organizations. Minoryx was founded in 2011, has operations in Spain and Belgium and has raised a total of €50M through Series A & B financing rounds. www.minoryx.com    


    Media Contacts & Analysts

    Andrew Lloyd & Associates Jo Reeder – Juliette dos Santos jo@ala.com / juliette@ala.com @ALA_Group + 44 1273 675 100


     

    Download English press release
  • Contact
    Headquarters
    https://www.minoryx.com/content/imgs/mail/logo.png
    Av. Ernest Lluch 32 - TCM3
    08302 Mataró
    (Barcelona) Spain
    info@minoryx.com 0034935441466+34 93 544 14 66
    Belgian R&D Site
    https://www.minoryx.com/content/imgs/mail/logo.png
    Rue Auguste Piccard 48, I - Tech Incubator
    6041 Gosselies
    (Charleroi) Belgium
    info@minoryx.com 003278700162+32 787 00 162
    Contact
    Follow us
    Legal Notice Privacy Policy Cookies Policy
    by eMascaró